Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2026)

Halozyme Therapeutics (HALO) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $47.5 million in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $47.5 million in Q1 2026; TTM through Mar 2026 was $47.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $42.9 million, down 57.25% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $47.5 million, up from $42.9 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for HALO reached as high as $100.4 million in Q4 2024 and fell as low as $3.3 million in Q2 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $32.1 million across 4 years, with a median of $21.3 million in 2022.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 31.24% in 2025 and fell as far as 57.25% in 2025.
• Year by year, Non-Current Deferred Tax Liability stood at $29.0 million in 2022, then soared by 246.36% to $100.4 million in 2024, then plunged by 57.25% to $42.9 million in 2025, then gained by 10.73% to $47.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $47.5 million in Q1 2026, $42.9 million in Q4 2025, and $8.2 million in Q3 2025.